First Patient Registered in Investigator-Sponsored Phase 2 Trial of Antigenics Inc. (New York)'s Oncophage Cancer Vaccine in Glioma

NEW YORK--(BUSINESS WIRE)--Antigenics Inc. (NASDAQ: AGEN) today announced that the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has initiated a Phase 2 clinical trial of Oncophage® (vitespen), Antigenics’ investigational patient-specific cancer vaccine, for the treatment of recurrent glioma. The primary objective of the investigator-sponsored study is to evaluate overall survival in glioma patients receiving Oncophage vaccination.

Back to news